KIDNEY DISEASE DRUG SAVES MONEY AND LIVE
A recent study has found that sevelamer (Renagel®) is having a positive long
term clinical and economic effect when used on hemodialysis patients. This
study, undertaken by the Caro Research Institute in Concord, MA and
published in Value in Health, examined the long-term consequences associated
with one year of sevelamer use.
“The safety and efficacy of sevelamer and its ability to attenuate the
progression of calcification have been well documented in a seminal clinical
study, but the study was not designed to assess the longer-term
implications,” says Krista Huybrechts who led the study.
Huybrechts’ team developed a simulation model based on the best available
evidence to date, and estimated that in the long-term, patients on sevelamer
have a 12% lower cardiovascular risk than those on calcium binders. The
savings accrued due to avoiding cardiovascular events largely offset by the
higher drug cost, leading to a favorable cost-effectiveness ratio of about
$2,200 per life year gained.
The results of this study now allows health policy makers and payers to
understand the value of sevelamer in the long-term where it could not have
been done from the clinical study alone.
Around 500,000 Americans suffer from Stage V chronic kidney disease (CKD)
and have a 10-20 times higher risk of cardiovascular mortality than the
This study is published in Value in Health. Media who wish to receive
a PDF of the article please contact
Krista Huybrechts, MS, is a Senior Researcher at the Caro Research
Institute in Concord, MA, USA, which specializes in epidemiology and health
economics. Prior to joining Caro Research in 1997, Krista held several
positions in health economics/outcomes research at the worldwide
headquarters of Janssen Pharmaceutica (J&J) in Belgium. Much of her work in
recent years has focused on quantifying the clinical and economic
implications of vascular calcifications in patients with ESRD. She can be
reached for questions or interviews at 978-371-1660 ext 151 (Monday through
About Value in Health
As the official publication of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR), Value in Health provides a
scientific forum for communicating health economics and outcomes research
methods and findings, furthering ISPOR's vision that "society allocate
scarce health care resources wisely, fairly, and efficiently." It is a
multidisciplinary peer-reviewed journal reporting on evaluations of medical
technologies including pharmaceuticals, biologics, devices, procedures, and
other health care interventions.
About Blackwell Publishing
Blackwell Publishing is the world’s leading society publisher,
partnering with more than 600 academic and professional societies. Blackwell
publishes over 750 journals annually and, to date has published close to
6,000 text and reference books, across a wide range of academic, medical,
and professional subjects.
To view the Untied Press International press release, go to:
Media Releases Index